MDxHealth SA ADR (MDXH)

Currency in USD
0.721
-0.001(-0.14%)
Closed·
0.700-0.021(-2.87%)
·
MDXH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.6800.750
52 wk Range
0.4005.330
Key Statistics
Prev. Close
0.722
Open
0.721
Day's Range
0.68-0.75
52 wk Range
0.4-5.33
Volume
277.13K
Average Volume (3m)
5.96M
1-Year Change
-79.6986%
Book Value / Share
-0.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDXH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.800
Upside
+149.65%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

MDxHealth SA ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1.800
(+149.65% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy2.00+177.39%4.00MaintainAug 21, 2026
Lake Street
Buy3.00+316.09%5.00MaintainAug 14, 2026
William Blair
Hold---DowngradeMay 14, 2026
Craig-Hallum
Buy3.00+316.09%8.00MaintainMay 14, 2026
Lake Street
Buy5.00+593.48%9.00MaintainMay 14, 2026

MDxHealth SA ADR Earnings Call Summary for Q2/2026

  • MDxHealth Q2 2026 revenue hit $27.2M, beating estimates of $25.89M with 16% YoY growth and record 14% sequential increase despite Resolve UTI discontinuation.
  • Company posted $0.18 loss per share vs. $0.17 estimate; gross margin compressed to 65.7% from 68.6% YoY due to product mix shift after ExoDx acquisition.
  • Full-year 2026 revenue guidance set at $110M-$115M, implying 20%-26% growth; management targets positive adjusted EBITDA by year-end 2026.
  • Pro forma cash position strengthened to $39.2M following $20M registered direct placement completed August 11, up from $19.2M at quarter-end.
  • Shares surged 33% after-hours to $0.615 on strong revenue momentum, though stock remains down 83% over past year at $24M market cap.
Last Updated: 2026-08-13, 05:40 p/m
Read Full Transcript

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.18 / -0.17
Revenue / Forecast
27.21M / 25.89M
EPS Revisions
Last 90 days

MDXH Income Statement

Compare MDXH to Peers and Sector

Metrics to compare
MDXH
Peers
Sector
Relationship
P/E Ratio
−1.9x−8.0x−0.4x
PEG Ratio
−0.370.830.00
Price/Book
−2.3x2.1x2.6x
Price / LTM Sales
0.6x18.3x3.1x
Upside (Analyst Target)
177.4%24.1%48.2%
Fair Value Upside
Unlock−15.1%6.5%Unlock

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
482.28K0.51%347.58K
Other Institutional Investors
64.75M67.86%46.67M
Public Companies & Retail Investors
30.19M31.63%21.75M
Total
95.42M100.00%68.77M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Bleichroeder LP33.17%31,648,56322,809
Lytton-Kambara Foundation12.14%11,583,0988,348

People Also Watch

6.28
JLHL
-4.41%
1.12
EHGO
-5.08%
5.320
AMIX
-5.51%
2.75
YXT
-5.50%

FAQ

What Is the MDxHealth ADR (MDXH) Stock Price Today?

The MDxHealth ADR stock price today is 0.721 USD.

What Stock Exchange Does MDxHealth ADR Trade On?

MDxHealth ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for MDxHealth ADR?

The stock symbol for MDxHealth ADR is "MDXH."

What Is the MDxHealth ADR Market Cap?

As of today, MDxHealth ADR market cap is 68.840M USD.

What Is MDxHealth ADR's Earnings Per Share (TTM)?

The MDxHealth ADR EPS (TTM) is -0.724.

When Is the Next MDxHealth ADR Earnings Date?

MDxHealth ADR will release its next earnings report on Nov 12, 2026.

From a Technical Analysis Perspective, Is MDXH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has MDxHealth ADR Stock Split?

MDxHealth ADR has split 1 times.

How Many Employees Does MDxHealth ADR Have?

MDxHealth ADR has 364 employees.

What is the current trading status of MDxHealth ADR (MDXH)?

As of Aug 29, 2026, MDxHealth ADR (MDXH) is trading at a price of 0.721 USD, with a previous close of 0.722 USD. The stock has fluctuated within a day range of 0.680 USD to 0.750 USD, while its 52-week range spans from 0.400 USD to 5.330 USD.

What Is MDxHealth ADR (MDXH) Price Target According to Analysts?

The average 12-month price target for MDxHealth ADR is 1.800 USD, with a high estimate of 3 USD and a low estimate of 1 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +149.65% Upside potential.

What Is the MDXH Premarket Price?

MDXH's last pre-market stock price is 0.711 USD. The pre-market share volume is 11,300.000, and the stock has decreased by -0.011, or -1.520%.

What Is the MDXH After Hours Price?

MDXH's last after hours stock price is 0.700 USD, the stock has decreased by -0.021, or -2.870%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.